top of page


52North raises £3.2 million to bring finger-prick cancer test closer to patients
52North, a University of Cambridge spin-out and a company that Milltrust Ventures invested in 2022 via the Future Health Fund, has raised £3.2 million in an early-stage funding round to accelerate clinical validation, regulatory progression and the UK launch of its lead product, Neutrocheck — a rapid, finger-prick blood test built to catch one of chemotherapy's most dangerous complications before it becomes an emergency. A test built to ease pressure on emergency care Neutroc
2 min read


Oncoshot partners up with Mitsui & Co. Ltd. on Asia-US clinical data collaboration built on IHH's clinical data
We're proud to share that Oncoshot — a Milltrust Ventures portfolio company — has signed a service agreement with Mitsui & Co., Ltd. to deploy its AI platform across IHH Healthcare's hospital network. IHH runs 89 hospitals across 10 countries under brands including Gleneagles, Mount Elizabeth Hospitals, Singapore, Parkway Shenton Pte Ltd, and Fortis Healthcare — and Mitsui, its largest shareholder, is bringing Oncoshot in to standardise oncology data, shorten clinical trial t
1 min read
bottom of page
